Table 1.
Baseline Characteristics of 367 Patients With Liver Cancers Who Underwent DEB-TACE Treatment
| Parameters | Patients (N = 367) |
|---|---|
| Age (years) | 59.95 ± 11.60 |
| Gender (female/male) | 286/81 |
| History of HB [n (%)] | 244 (66.5) |
| History of HC [n (%)] | 5 (1.4) |
| History of drink [n (%)] | 153 (41.7) |
| History of cirrhosis [n (%)] | 176 (48.0) |
| Histology | |
| Primary HCC [n (%)] | 275 (74.9) |
| Primary ICC [n (%)] | 37 (10.1) |
| Secondary liver cancer [n (%)] | 55 (15.0) |
| Tumor distribution | |
| Multifocal [n (%)] | 244 (66.5) |
| Unifocal [n (%)] | 123 (33.5) |
| Tumor location | |
| Left liver [n (%)] | 56 (15.3) |
| Right liver [n (%)] | 183 (49.9) |
| Bilobar [n (%)] | 128 (34.9) |
| Largest nodule size (cm) | 4.80 (2.70–8.30) |
| Portal vein invasion [n (%)] | 103 (28.1) |
| Hepatic vein invasion [n (%)] | 48 (13.1) |
| ECOG performance status | |
| 0 [n (%)] | 200 (54.5) |
| 1 [n (%)] | 127 (34.6) |
| 2 [n (%)] | 30 (8.2) |
| 3 [n (%)] | 10 (2.7) |
| Child–Pugh stage (for HCC and ICC, n = 312) | |
| A [n (%)] | 261 (83.7) |
| B [n (%)] | 49 (15.7) |
| C [n (%)] | 2 (0.6) |
| BCLC stage (for HCC and ICC, n = 312) | |
| 0 [n (%)] | 1 (0.3) |
| A [n (%)] | 76 (24.4) |
| B [n (%)] | 119 (38.1) |
| C [n (%)] | 115 (36.9) |
| D [n (%)] | 1 (0.3) |
| Cycles of DEB-TACE treatment | |
| 1 cycle [n (%)] | 305 (83.1) |
| 2 or more cycles [n (%)] | 62 (16.9) |
| Blood routine | |
| WBC (×109 cell/L) | 5.16 (4.00–6.60) |
| RBC (×1012 cell/L) | 4.27 (3.80–4.69) |
| ANC (%) | 61.2 (52.5–69.4) |
| Hb (g/L) | 127 (109–142) |
| PLT (×109 cell/L) | 124 (76–178) |
| Liver function | |
| ALB (g/L) | 39.6 (36.2–43.7) |
| TP (g/L) | 69.4 (64.6–73.8) |
| TBIL (μmol/L) | 14.5 (11.0–22.0) |
| TBA (I/L) | 10.0 (6.0–22.2) |
| ALT (U/L) | 27.0 (19.0–40.0) |
| AST (U/L) | 35.0 (25.0–53.0) |
| ALP (U/L) | 117 (85–164) |
| Kidney function | |
| BCr (μmol/L) | 70.0 (60.0–80.0) |
| BUN (mmol/L) | 4.90 (3.94–6.10) |
| Tumor markers | |
| AFP (μg/L) | 21.5 (3.6–562.2) |
| CEA (μg/L) | 2.9 (1.9–5.1) |
| CA199 (ku/L) | 15.4 (6.6–40.5) |
| Previous treatments | |
| cTACE [n (%)] | 138 (37.6) |
| Surgery [n (%)] | 109 (29.7) |
| Systematic chemotherapy [n (%)] | 46 (12.5) |
| Radiofrequency ablation [n (%)] | 53 (14.4) |
| Targeted therapy [n (%)] | 12 (3.3) |
| DEBs size | |
| 100–300 μm [n (%)] | 354 (96.5) |
| 300–500 μm [n (%)] | 13 (3.5) |
| Drug dosage | |
| Low dose [n (%)] | 34 (9.3) |
| Normal dose [n (%)] | 333 (90.7) |
| Chemoembolization reagents (440 DEB-TACE records) | |
| Anthracyclines [n (%)] | 387 (88.0) |
| Irinotecan [n (%)] | 53 (12.0) |
| Combination of ordinary embolization agent [n (%)] | 116 (31.6) |
Data are presented as mean ± standard deviation, median (25th–75th), or count (%). HB, hepatitis B; HC, hepatic C; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; DEB-TACE, drug-eluting bead transarterial chemoembolization; WBC, white blood cell; RBC, red blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; ALB, albumin; TP, total protein; TBIL, total bilirubin; TBA, total bile acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; BCr, blood creatinine; BUN, blood urea nitrogen; AFP, alpha fetoprotein; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen199; cTACE, conventional transarterial chemoembolization.